Stephen D. Smith

4.9k total citations
125 papers, 1.6k citations indexed

About

Stephen D. Smith is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Stephen D. Smith has authored 125 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Pathology and Forensic Medicine, 60 papers in Oncology and 50 papers in Genetics. Recurrent topics in Stephen D. Smith's work include Lymphoma Diagnosis and Treatment (82 papers), Chronic Lymphocytic Leukemia Research (44 papers) and CAR-T cell therapy research (26 papers). Stephen D. Smith is often cited by papers focused on Lymphoma Diagnosis and Treatment (82 papers), Chronic Lymphocytic Leukemia Research (44 papers) and CAR-T cell therapy research (26 papers). Stephen D. Smith collaborates with scholars based in United States, South Africa and France. Stephen D. Smith's co-authors include Eric D. Hsi, Raymond Lai, Sarah L. Ondrejka, Ajay K. Gopal, Mazyar Shadman, Ariel L. Rivas, Brian G. Till, Ryan D. Cassaday, Shuo Ma and Graham P. Collins and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Stephen D. Smith

113 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stephen D. Smith United States	21	968	743	579	268	253	125	1.6k
Ismael Buño Spain	22	309 0.3×	432 0.6×	313 0.5×	799 3.0×	378 1.5×	105	1.8k
Yoshitaka Imaizumi Japan	23	402 0.4×	411 0.6×	141 0.2×	169 0.6×	367 1.5×	111	1.9k
David H. Dreyfus United States	20	505 0.5×	429 0.6×	377 0.7×	48 0.2×	171 0.7×	45	1.5k
Matthias Karrasch Germany	16	208 0.2×	576 0.8×	129 0.2×	35 0.1×	486 1.9×	42	1.5k
H. Kaufmann Austria	23	315 0.3×	549 0.7×	334 0.6×	836 3.1×	907 3.6×	71	1.7k
Catherine Péronne France	13	231 0.2×	382 0.5×	125 0.2×	97 0.4×	264 1.0×	14	1.9k
MJ Robertson United States	9	228 0.2×	383 0.5×	104 0.2×	374 1.4×	155 0.6×	16	1.4k
Erik Svedmyr Sweden	25	387 0.4×	769 1.0×	113 0.2×	103 0.4×	181 0.7×	53	1.9k
M. Durm United States	9	250 0.3×	231 0.3×	308 0.5×	281 1.0×	236 0.9×	9	1.7k
Hans‐Jürgen Gruss Germany	16	291 0.3×	547 0.7×	110 0.2×	66 0.2×	159 0.6×	21	1.4k

Countries citing papers authored by Stephen D. Smith

Since Specialization

Citations

This map shows the geographic impact of Stephen D. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen D. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen D. Smith more than expected).

Fields of papers citing papers by Stephen D. Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen D. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen D. Smith. The network helps show where Stephen D. Smith may publish in the future.

Co-authorship network of co-authors of Stephen D. Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen D. Smith. A scholar is included among the top collaborators of Stephen D. Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen D. Smith. Stephen D. Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Poh, Christina, Xueyan Chen, Jenna Voutsinas, et al.. (2025). Impact of immunophenotype on clinical disease characteristics and outcomes in T‐cell prolymphocytic leukaemia. British Journal of Haematology. 207(5). 2143–2146.

Poh, Christina, Jenna Voutsinas, Mazyar Shadman, et al.. (2025). Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas. Blood Advances. 9(15). 4037–4042. 1 indexed citations

Poh, Christina, Victor A. Chow, Ryan C. Lynch, et al.. (2024). Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis. Transplantation and Cellular Therapy. 30(2). S33–S33.

Villasboas, José C., Stephen D. Smith, Carlos Grande, et al.. (2024). Phase 1/2 of EO2463 immunotherapy as monotherapy and in combination with lenalidomide and/or rituximab in indolent NHL (EONHL1-20/SIDNEY).. Journal of Clinical Oncology. 42(16_suppl). 7058–7058. 1 indexed citations

Assouline, Sarit, Lihua E. Budde, Julio C. Chávez, et al.. (2024). Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL).. Journal of Clinical Oncology. 42(16_suppl). 7021–7021.

Assouline, Sarit, Lihua E. Budde, Julio C. Chávez, et al.. (2024). Mosunetuzumab With Polatuzumab Vedotin: Subgroup Analyses in Patients (pts) With Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL). Clinical Lymphoma Myeloma & Leukemia. 24. S212–S212. 1 indexed citations

Lynch, Ryan C., Christine D Crider, Stephanie Louie, et al.. (2023). Predictors of Outcomes with Venetoclax-Based Treatment in Patients with Progressive Disease or Intolerance after Covalent BTK Inhibitors. Blood. 142(Supplement 1). 4656–4656.

Poh, Christina, Victor A. Chow, Ryan C. Lynch, et al.. (2023). Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis. Blood. 142(Supplement 1). 2129–2129. 1 indexed citations

Lynch, Ryan C., Ryan D. Cassaday, Stephen D. Smith, et al.. (2021). Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. The Lancet Haematology. 8(8). e562–e571. 33 indexed citations

10.

Graf, Solomon A., Ryan D. Cassaday, Karolyn Morris, et al.. (2020). Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 21(3). 176–181. 10 indexed citations

11.

Tuazon, Sherilyn A., Ryan D. Cassaday, Theodore A. Gooley, et al.. (2020). Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma. Transplantation and Cellular Therapy. 27(1). 57.e1–57.e8. 5 indexed citations

12.

Cassaday, Ryan D., Jonathan R. Fromm, Andrew J. Cowan, et al.. (2017). Radiographic and High-Throughput Sequencing (HTS)-Based Response Assessment after Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Updated Results of a Phase I/II Trial. Blood. 130. 2806–2806. 9 indexed citations

13.

Tseng, Yolanda D., Philip A. Stevenson, Ryan D. Cassaday, et al.. (2017). Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma. Biology of Blood and Marrow Transplantation. 24(2). 282–287. 9 indexed citations

14.

Graf, Solomon A., Philip A. Stevenson, Leona Holmberg, et al.. (2015). Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. Annals of Oncology. 26(11). 2323–2328. 20 indexed citations

15.

Mandawat, Aditya, et al.. (2011). Cauda equina lymphoma: a case report including postmortem examination.. PubMed. 9(5). 414–18. 2 indexed citations

16.

Hill, Brian T., Lisa Rybicki, Brian J. Bolwell, et al.. (2011). The non‐relapse mortality rate for patients with diffuse large B‐cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls. British Journal of Haematology. 152(5). 561–569. 37 indexed citations

17.

Smith, Stephen D., Brian J. Bolwell, Anjali S. Advani, et al.. (2009). High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison withde novodiffuse large B-cell lymphoma. Leukemia & lymphoma. 50(10). 1625–1631. 10 indexed citations

18.

Chowell, Gerardo, Ariel L. Rivas, Stephen D. Smith, & James M. Hyman. (2006). Identification of case clusters and counties with high infective connectivity in the 2001 epidemic of foot-and-mouth disease in Uruguay. American Journal of Veterinary Research. 67(1). 102–113. 13 indexed citations

19.

Smith, Stephen D., et al.. (2005). Antiplatelet Therapy and Anticoagulation in Patients With Giant Cell Arteritis. Investigative Ophthalmology & Visual Science. 46(13). 646–646. 1 indexed citations

20.

Rivas, Ariel L., Steven J. Schwager, Stephen D. Smith, & Andrea Magrì. (2004). Early and Cost‐Effective Identification of High Risk/Priority Control Areas in Foot‐and‐Mouth Disease Epidemics. Journal of Veterinary Medicine Series B. 51(6). 263–271. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact